Evogene Showcases Breakthroughs in Pharma Technology at BIO International Convention

Evogene Presents Innovations in Pharma at BIO International Convention

Evogene Ltd., an innovative player in computational chemistry, is set to take the stage at the BIO International Convention in San Diego, California, from June 22 to 25, 2026. This annual event attracts a plethora of companies and professionals interested in biotechnology and pharmaceutical advancements. Evogene, listed on NASDAQ (EVGN) and TASE (EVGN), stands out in the field, focusing on cutting-edge AI technologies that are revolutionizing drug discovery processes.

The company will have a strong representation at the event, with Ofer Haviv, President and CEO, Dr. Gabi Tarcic, Chief Development Officer, and Dr. Olga Nissan, VP of Business Development, attending. Dr. Tarcic is scheduled to present a significant talk on June 23, 2026, at 2:00 PM PT in Theater 1. This session promises to showcase Evogene’s latest technological developments, particularly regarding AI-driven small-molecule discovery and optimization.

Evogene's cornerstone technology, ChemPass AI™, is designed for generative chemical exploration, which enables the creation of novel and highly potent small molecules. This innovation focuses on optimizing various critical parameters essential for drug development. By employing this advanced generative AI, Evogene seeks to align its pharmaceutical innovations with practical industry needs, paving the way for significant breakthroughs in drug development.

In addition to the presentation, Evogene encourages attendees to engage in one-on-one meetings with their management team. This interactive approach aims to foster collaborative discussions with pharmaceutical and biotechnology partners. Interested individuals or parties are invited to connect with Evogene's investor relations or public relations teams for scheduling.

The BIO International Convention is known for being a networking hub for experts across the biotech and pharmaceutical industries. Evogene's participation this year not only highlights its ongoing commitment to innovation but also reinforces its stature in a competitive market where advanced science and technology meet business requirements.

Evogene’s goal is to establish strategic partnerships while also driving internal product development to bolster both pharmaceutical and agricultural sectors. With the integration of scientific and technical expertise, the company aims to enhance its product offerings and expand its impact in the respective industries.

In summary, the upcoming BIO International Convention serves as a critical platform for Evogene to reveal its strides in the pharmaceutical domain, particularly highlighting the innovative capabilities of ChemPass AI™. The contributions made by Evogene in the realm of computational chemistry reflect a commitment to improving drug discovery processes and contributing positively to the biomedical landscape.

To learn more about Evogene and its pharmaceutical innovations, visit Evogene’s website.